Greenwich LifeSciences (GLSI) - Cash on Hand per Share

Corporate emblem and logo of Greenwich LifeSciences Inc (GLSI)

Cash per share helps assess the liquidity of Greenwich LifeSciences (GLSI), which is developing GP2 immunotherapy through partnerships with oncology centers. A lack of sales and reliance on external capital preclude financial stability, although the research base functions flawlessly. The current 0.40 metric determines this level, demonstrating the volume of free cash per share to minimize default risks.

Greenwich LifeSciences, Inc - GLSI Cash per Single Share (period 07/04/2022 - 11/20/2026)

Comprehensive metric breakdowns and analytics for Greenwich LifeSciences Inc. (GLSI)

- cash position and cash flow details:
Summary company analysis:Greenwich LifeSciences - GLSI
Manufactured product of Greenwich LifeSciences, Inc.

Maintaining a precision cold chain in oncology requires significant operational reserves, making liquidity critical for the continuity of Greenwich LifeSciences (GLSI) supplies. An analysis of cash per share demonstrates the proportional volume of free cash flow, allowing investors to assess the burn rate and the company's ability to avoid debt default during periods of revenue volatility.